急性白血病患者出血与静脉血栓栓塞的生物标志物
研究纳入358例新诊断急性白血病患者(29例APL、253例非APL急性髓系白血病、76例急性淋巴细胞白血病)和30例正常对照,检测凝血与纤溶通路标志物,并用多变量回归分析其与出血和深静脉血栓的关联。急性白血病患者EVTF活性、磷脂酰丝氨酸阳性细胞外囊泡、PAI-1、纤溶酶-抗纤溶酶复合物及游离DNA水平高于正常对照,而瓜氨酸化组蛋白H3-DNA复合物水平较低。高EVTF活性与出血风险增加相关(亚分布风险比2.30,95%CI 0.99-5.31),高PAI-1水平与DVT风险增加相关(亚分布风险比3.00,95%CI 0.95-9.47)。
要点
- 急性白血病患者EVTF活性、PAI-1等标志物水平高于正常对照。
- 高EVTF活性与出血风险增加相关(亚分布风险比2.30,95%CI 0.99-5.31)。
- 高PAI-1水平与DVT风险增加相关(亚分布风险比3.00,95%CI 0.95-9.47)。
核心结论
- 研究显示急性白血病患者存在多个生物标志物的改变,并识别出与出血和DVT风险相关的生物标志物。
研究设计与样本
- 研究检测年龄≥18岁新诊断急性白血病患者与正常对照的血浆凝血及纤溶通路激活物、抑制物和标志物水平。
- 采用多变量回归模型分析急性白血病患者中生物标志物与出血和DVT的关联。
- 研究纳入358例急性白血病患者(29例APL、253例非APL急性髓系白血病、76例急性淋巴细胞白血病)和30例正常对照。
主要发现
- 急性白血病患者EVTF活性、磷脂酰丝氨酸阳性细胞外囊泡、PAI-1、纤溶酶-抗纤溶酶复合物及游离DNA水平高于正常对照,瓜氨酸化组蛋白H3-DNA复合物水平低于正常对照。
- APL患者在急性白血病患者中EVTF活性最高、组织型纤溶酶原激活物水平最低。
- 急性白血病患者中共发生41例出血事件和23例DVT事件。
- 高EVTF活性与出血风险增加相关(亚分布风险比2.30,95%CI 0.99-5.31)。
- 高PAI-1水平与DVT风险增加相关(亚分布风险比3.00,95%CI 0.95-9.47)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulopathy and associated bleeding and deep vein thrombosis (DVT) are major causes of morbidity and mortality in patients with acute leukemia. The underlying mechanisms of these complications have not been fully elucidated. OBJECTIVES: To evaluate the associations between biomarker levels and bleeding and DVT in acute leukemia patients. METHODS: We examined plasma levels of activators, inhibitors, and biomarkers of the coagulation and fibrinolytic pathways in patients aged ≥18 years with newly diagnosed acute leukemia compared with those of normal controls. Multivariable regression models were used to examine the association of biomarkers with bleeding and DVT in acute leukemia patients. The study included 358 patients with acute leukemia (29 with acute promyelocytic leukemia [APL], 253 with non-APL acute myeloid leukemia, and 76 with acute lymphoblastic leukemia) and 30 normal controls. RESULTS: Patients with acute leukemia had higher levels of extracellular vesicle tissue factor (EVTF) activity, phosphatidylserine-positive extracellular vesicles, plasminogen activator inhibitor-1, plasmin-antiplasmin complexes, and cell-free DNA and lower levels of citrullinated histone H3-DNA complexes compared with normal controls. APL patients had the highest levels of EVTF activity and the lowest levels of tissue plasminogen activator among acute leukemia patients. There were 41 bleeding and 23 DVT events in acute leukemia patients. High EVTF activity was associated with increased risk of bleeding (subdistribution hazard ratio, 2.30; 95% CI, 0.99-5.31), whereas high levels of plasminogen activator inhibitor-1 were associated with increased risk of DVT (subdistribution hazard ratio, 3.00; 95% CI, 0.95-9.47) in these patients. CONCLUSION: Our study shows alterations in several biomarkers in acute leukemia and identifies biomarkers associated with risk of bleeding and DVT.
引用
- Hisada Y, Archibald SJ, Bansal K, et al. Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia. J Thromb Haemost. 2024. PMID: 38574862. doi:10.1016/j.jtha.2024.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。